Home Compare ROG.SW vs WST
Stock Comparison · Close comparison

Roche Holding vs West Pharmaceutical Services: Which Stock Looks Stronger in 2026?

The structural profiles are close, with West Pharmaceutical Services carrying a narrow edge on growth. The remaining gap is narrow enough that the comparison remains open to different readings. The market setup is currently leaning toward Roche, which does not confirm the structural lead. That leaves a split case: the structural lead stays with West Pharmaceutical Services, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison stays tight enough that no single part of the profile fully breaks it open.

Trajectory Similarity
0.68
Moderately similar
Peer-set rank: #11
within Roche Holding AG's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The match is driven mainly by capital structure and revenue stability.

Similarity drivers
capital structurerevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
ROG.SW
Roche Holding AG
63
Peer-Score
Signal qualityHigh
vs
WST
West Pharmaceutical Services, Inc.
67
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: ROG.SW vs WST Profitability 75 84 Stability 51 50 Valuation 64 61 Growth 55 66 ROG.SW WST
Gap Ranking
#1 Growth +11
#2 Profitability +9
#3 Valuation +3
#4 Stability +1
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ROG.SW and WST Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ROG.SWWST Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against West Pharmaceutical Services, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both look solid on growth, though West Pharmaceutical Services, Inc. still holds the stronger peer position.
Profitability
On profitability, the edge still sits with West Pharmaceutical Services, Inc., even though both profiles look solid.
Growth — Dominant Gap
ROG.SW
55
WST
66
Gap+11in favour of WST

One company is still expanding while the other is contracting, which creates a very wide growth split.

What keeps the gap from being one-sided

Roche Holding AG still looks less cycle-sensitive — that keeps the result from looking completely one-sided.

What this means for the comparison

The result is clear, but the profile still looks more volatile than a fully settled winner.

Explore full peer positioning in AssetNext

Break down the ROG.SW vs WST comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other close comparisons

Explore how ROG.SW and WST each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.